The intellectual disability that characterizes Down syndrome (DS) is primarily caused by prenatal changes in central nervous system growth and differentiation. However, in later life stages, the cognitive abilities of DS individuals progressively decline due to accelerated aging and the development of Alzheimer's disease (AD) neuropathology. The AD neuropathology in DS has been related to the overexpression of several genes encoded by Hsa21 including DYRK1A (dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A), which encodes a protein kinase that performs crucial functions in the regulation of multiple signaling pathways that contribute to normal brain development and adult brain physiology. Studies performed in vitro and in vivo in animal models overexpressing this gene have demonstrated that the DYRK1A gene also plays a crucial role in several neurodegenerative processes found in DS. The Ts65Dn (TS) mouse bears a partial triplication of several Hsa21 orthologous genes, including Dyrk1A, and replicates many DS-like abnormalities, including age-dependent cognitive decline, cholinergic neuron degeneration, increased levels of APP and Aβ, and tau hyperphosphorylation. To use a more direct approach to evaluate the role of the gene dosage of Dyrk1A on the neurodegenerative profile of this model, TS mice were crossed with Dyrk1A KO mice to obtain mice with a triplication of a segment of Mmu16 that includes this gene, mice that are trisomic for the same genes but only carry two copies of Dyrk1A, euploid mice with a normal Dyrk1A dosage, and CO animals with a single copy of Dyrk1A. Normalizing the gene dosage of Dyrk1A in the TS mouse rescued the density of senescent cells in the cingulate cortex, hippocampus and septum, prevented cholinergic neuron degeneration, and reduced App expression in the hippocampus, Aβ load in the cortex and hippocampus, the expression of phosphorylated tau at the Ser202 residue in the hippocampus and cerebellum and the levels of total tau in the cortex, hippocampus and cerebellum. Thus, the present study provides further support for the role of the Dyrk1A gene in several AD-like phenotypes found in TS mice and indicates that this gene could be a therapeutic target to treat AD in DS.
Introduction
Down syndrome (DS) is the most common genetic cause of intellectual disability (Shin et al., 2009) and is primarily caused by prenatal changes in central nervous system growth and differentiation (Lott, 2012; Haydar and Reeves, 2012) . However, in later life stages, the cognitive abilities of DS individuals progressively decline due to accelerated aging and to the development of Alzheimer's disease (AD) neuropathology. The primary hallmarks of AD, such as the accumulation of amyloid plaques composed of β-amyloid (Aβ) peptides, neurofibrillary tangles (NFTs) formed by insoluble deposits of abnormally hyperphosphorylated tau, neuroinflammation, synapse and neuron loss and regional atrophy, are present in 100% of individuals with DS by the fourth decade of life (Wilcock and Griffin, 2013; Lott, 2012; Cenini et al., 2012; Sabbagh et al., 2011; Lott and Dierssen, 2010; Teipel and Hampel, 2006) . This high prevalence of AD neuropathology in DS has been partially related to the overexpression of several AD-related genes encoded by Hsa21. One of these genes is APP (Amyloid Precursor Protein) and its triplication in DS leads to an increase in the production of Aβ peptides. An imbalance between Aβ production and clearance leads to high levels of these peptides, causing their fast aggregation and deposition in plaques, which can induce other AD-associated neuropathologies such as the increase in oxidative stress, neuroinflammation, neuronal death and the acceleration of the decline in learning and memory (Wilcock, 2012; Sipos et al., 2007; Eikelenboom et al., 2006; Hardy, 2006; Hardy and Higgins 1992) .
Among the other trisomic genes that have been implicated in the cognitive decline and AD-related neuropathology observed in DS individuals is dual-specificity tyrosine-(Y)-phosphorylation regulated Neurobiology of Disease 106 (2017) 76-88 
